Stifel Starts Rapt Therapeutics (RAPT) at Buy, 'RPT193 Has a Shot at Being a First-in-Class Non-JAK Oral for Atopic Dermatitis'
Tweet Send to a Friend
(Updated - August 8, 2023 4:07 PM EDT)
Stifel analyst Alex Thompson initiates coverage on Rapt Therapeutics (NASDAQ: RAPT) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Alex Thompson initiates coverage on Rapt Therapeutics (NASDAQ: RAPT) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
